Skip to main content
Erschienen in: Archives of Gynecology and Obstetrics 4/2024

28.03.2023 | Maternal-Fetal Medicine

The role of the PLGF in the management of pregnancies complicated with fetal microsomia

verfasst von: Athena P. Souka, M. I. Chatziioannou, A. Pegkou, P. Antsaklis, G. Daskalakis

Erschienen in: Archives of Gynecology and Obstetrics | Ausgabe 4/2024

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To explore the contribution of maternal and fetal parameters in predicting the time interval between diagnosis and development of adverse events leading to delivery in singleton pregnancies complicated with fetal microsomia.

Methods

Prospective study on singleton pregnancies referred to a tertiary center because of suspicion of fetal smallness in the third trimester. The study cohort included cases with fetal abdominal circumference (AC) ≤ 10th centile or estimated fetal weight ≤ 10th centile or umbilical artery pulsatitlity index ≥ 90th centile. Development of pre-eclampsia, fetal demise, and fetal deterioration diagnosed by fetal Doppler studies or fetal heart rate monitoring and leading to delivery were considered as adverse events. Maternal demographics, obstetric history, blood pressure, serum PLGF, and fetal Doppler studies were explored as predictors of the time interval between the first visit to the clinic and the diagnosis of complications.

Results

In 59 women, the median incubation period from presentation to the clinic to an adverse event was 6, 2 weeks, whereas half of the pregnancies (52.5%) did not develop any adverse event. PLGF was the strongest predictor of adverse events. Both PLGF in raw values and PLGF MOM had equally good predictive ability (AUC 0.82 and 0.78 respectively). Optimal cut-off points were 177.7 pg/ml for PLGF raw values (sensitivity 83% and specificity 66.7%) and 0.277 MoM (sensitivity 76% and specificity 86.7%). On multiple Cox regression analysis, maternal systolic blood pressure, PLGF, fetal increased umbilical artery PI, and reduced CP ratio were independently associated with adverse events. Half of the pregnancies with low PLGF and only one in ten with high PLGF were delivered within two weeks after the initial visit.

Conclusion

Half of the pregnancies carrying a small fetus in the third trimester will not develop maternal or fetal complications. PLGF is a strong predictor of adverse events that can be used to customize antenatal care.
Literatur
1.
Zurück zum Zitat Lindqvist PG, Molin J (2005) Does antenatal identification of small-for-gestational age fetuses significantly improve their outcome? Ultrasound Obstet Gynecol 25(3):258–264CrossRefPubMed Lindqvist PG, Molin J (2005) Does antenatal identification of small-for-gestational age fetuses significantly improve their outcome? Ultrasound Obstet Gynecol 25(3):258–264CrossRefPubMed
2.
Zurück zum Zitat Sharp A, Jackson R, Cornforth C, Harrold J, Turner MA, Kenny L, Baker PN, Johnstone ED, Khalil A, von Dadelszen P, Papageorghiou AT, Alfirevic Z (2019) A prediction model for short-term neonatal outcomes in severe early-onset fetal growth restriction. Eur J Obstet Gynecol Reprod Biol 241:109–118CrossRefPubMed Sharp A, Jackson R, Cornforth C, Harrold J, Turner MA, Kenny L, Baker PN, Johnstone ED, Khalil A, von Dadelszen P, Papageorghiou AT, Alfirevic Z (2019) A prediction model for short-term neonatal outcomes in severe early-onset fetal growth restriction. Eur J Obstet Gynecol Reprod Biol 241:109–118CrossRefPubMed
3.
Zurück zum Zitat Papastefanou I, Pilalis A, Chrelias C, Kassanos D, Souka AP (2014) Screening for birth weight deviations by second and third trimester ultrasound scan. Prenat Diagn 34(8):759–764CrossRefPubMed Papastefanou I, Pilalis A, Chrelias C, Kassanos D, Souka AP (2014) Screening for birth weight deviations by second and third trimester ultrasound scan. Prenat Diagn 34(8):759–764CrossRefPubMed
4.
Zurück zum Zitat Bakalis S, Peeva G, Gonzalez R, Poon LC, Nicolaides KH (2015) Prediction of small-for-gestational-age neonates: screening by biophysical and biochemical markers at 30–34 weeks. Ultrasound Obstet Gynecol 46(4):446–451CrossRefPubMed Bakalis S, Peeva G, Gonzalez R, Poon LC, Nicolaides KH (2015) Prediction of small-for-gestational-age neonates: screening by biophysical and biochemical markers at 30–34 weeks. Ultrasound Obstet Gynecol 46(4):446–451CrossRefPubMed
5.
Zurück zum Zitat Tan MY, Syngelaki A, Poon LC, Rolnik DL, O’Gorman N, Delgado JL, Akolekar R, Konstantinidou L, Tsavdaridou M, Galeva S, Ajdacka U, Molina FS, Persico N, Jani JC, Plasencia W, Greco E, Papaioannou G, Wright A, Wright D, Nicolaides KH (2018) Screening for pre-eclampsia by maternal factors and biomarkers at 11–13 weeks’ gestation. Ultrasound Obstet Gynecol 52(2):186–195CrossRefPubMed Tan MY, Syngelaki A, Poon LC, Rolnik DL, O’Gorman N, Delgado JL, Akolekar R, Konstantinidou L, Tsavdaridou M, Galeva S, Ajdacka U, Molina FS, Persico N, Jani JC, Plasencia W, Greco E, Papaioannou G, Wright A, Wright D, Nicolaides KH (2018) Screening for pre-eclampsia by maternal factors and biomarkers at 11–13 weeks’ gestation. Ultrasound Obstet Gynecol 52(2):186–195CrossRefPubMed
6.
Zurück zum Zitat Chaiworapongsa T, Romero R, Whitten AE, Korzeniewski SJ, Chaemsaithong P, Hernandez-Andrade E, Yeo L, Hassan SS (2016) The use of angiogenic biomarkers in maternal blood to identify which SGA fetuses will require a preterm delivery and mothers who will develop pre-eclampsia. J Matern Fetal Neonatal Med 29(8):1214–1228CrossRefPubMedPubMedCentral Chaiworapongsa T, Romero R, Whitten AE, Korzeniewski SJ, Chaemsaithong P, Hernandez-Andrade E, Yeo L, Hassan SS (2016) The use of angiogenic biomarkers in maternal blood to identify which SGA fetuses will require a preterm delivery and mothers who will develop pre-eclampsia. J Matern Fetal Neonatal Med 29(8):1214–1228CrossRefPubMedPubMedCentral
7.
Zurück zum Zitat Valiño N, Giunta G, Gallo DM, Akolekar R, Nicolaides KH (2016) Biophysical and biochemical markers at 35–37 weeks’ gestation in the prediction of adverse perinatal outcome. Ultrasound Obstet Gynecol 47(2):203–209CrossRefPubMed Valiño N, Giunta G, Gallo DM, Akolekar R, Nicolaides KH (2016) Biophysical and biochemical markers at 35–37 weeks’ gestation in the prediction of adverse perinatal outcome. Ultrasound Obstet Gynecol 47(2):203–209CrossRefPubMed
8.
Zurück zum Zitat Miranda J, Triunfo S, Rodriguez-Lopez M, Sairanen M, Kouru H, Parra-Saavedra M, Crovetto F, Figueras F, Crispi F, Gratacós E (2017) Performance of third-trimester combined screening model for prediction of adverse perinatal outcome. Ultrasound Obstet Gynecol 50(3):353–360CrossRefPubMed Miranda J, Triunfo S, Rodriguez-Lopez M, Sairanen M, Kouru H, Parra-Saavedra M, Crovetto F, Figueras F, Crispi F, Gratacós E (2017) Performance of third-trimester combined screening model for prediction of adverse perinatal outcome. Ultrasound Obstet Gynecol 50(3):353–360CrossRefPubMed
9.
Zurück zum Zitat Quezada MS, Rodriguez-Calvo J, Villalain C, Gomez-Arriaga PI, Galindo A, Herraiz I (2020) sFlt-1/PlGF ratio and timing of delivery in early-onset fetal growth restriction with antegrade umbilical artery flow. Ultrasound Obstet Gynecol 56:549–556CrossRefPubMed Quezada MS, Rodriguez-Calvo J, Villalain C, Gomez-Arriaga PI, Galindo A, Herraiz I (2020) sFlt-1/PlGF ratio and timing of delivery in early-onset fetal growth restriction with antegrade umbilical artery flow. Ultrasound Obstet Gynecol 56:549–556CrossRefPubMed
10.
Zurück zum Zitat Shim SH, Jeon HJ, Ryu HJ, Kim SH, Min SG, Kang MK, Park HJ, Cha DH (2021) Prenatal serum sFlt-1/PlGF ratio predicts the adverse neonatal outcomes among small-for-gestational-age fetuses in normotensive pregnant women: A prospective cohort study. Medicine (Baltimore) 100(8):24681CrossRef Shim SH, Jeon HJ, Ryu HJ, Kim SH, Min SG, Kang MK, Park HJ, Cha DH (2021) Prenatal serum sFlt-1/PlGF ratio predicts the adverse neonatal outcomes among small-for-gestational-age fetuses in normotensive pregnant women: A prospective cohort study. Medicine (Baltimore) 100(8):24681CrossRef
11.
Zurück zum Zitat Andrikos A, Andrikos D, Schmidt B, Birdir C, Kimmig R, Gellhaus A, Köninger A (2022) Course of the sFlt-1/PlGF ratio in fetal growth restriction and correlation with biometric measurements, feto-maternal Doppler parameters and time to delivery. Arch Gynecol Obstet 305:597–605CrossRefPubMed Andrikos A, Andrikos D, Schmidt B, Birdir C, Kimmig R, Gellhaus A, Köninger A (2022) Course of the sFlt-1/PlGF ratio in fetal growth restriction and correlation with biometric measurements, feto-maternal Doppler parameters and time to delivery. Arch Gynecol Obstet 305:597–605CrossRefPubMed
12.
Zurück zum Zitat Sherrell H, Dunn L, Clifton V, Kumar S (2018) Systematic review of maternal Placental Growth Factor levels in late pregnancy as a predictor of adverse intrapartum and perinatal outcomes. Eur J Obstet Gynecol Reprod Biol 225:26–34CrossRefPubMed Sherrell H, Dunn L, Clifton V, Kumar S (2018) Systematic review of maternal Placental Growth Factor levels in late pregnancy as a predictor of adverse intrapartum and perinatal outcomes. Eur J Obstet Gynecol Reprod Biol 225:26–34CrossRefPubMed
13.
Zurück zum Zitat ISUOG Practice Guidelines (2019) ultrasound assessment of fetal biometry and growth. Ultrasound Obstet Gynecol 53:715–723CrossRef ISUOG Practice Guidelines (2019) ultrasound assessment of fetal biometry and growth. Ultrasound Obstet Gynecol 53:715–723CrossRef
14.
Zurück zum Zitat Roberts JM et al (2013) American college of obstetricians and gynecologists; task force on hypertension in pregnancy: hypertension in pregnancy report of the american college of obstetricians and gynecologists task force on hypertension in pregnancy. Obstet Gynecol 122:1122–1131 Roberts JM et al (2013) American college of obstetricians and gynecologists; task force on hypertension in pregnancy: hypertension in pregnancy report of the american college of obstetricians and gynecologists task force on hypertension in pregnancy. Obstet Gynecol 122:1122–1131
15.
Zurück zum Zitat Wright D, Gallo DM, Gil Pugliese S, Casanova C, Nicolaides KH (2016) Contingent screening for preterm pre-eclampsia. Ultrasound Obstet Gynecol 47:554–559CrossRefPubMed Wright D, Gallo DM, Gil Pugliese S, Casanova C, Nicolaides KH (2016) Contingent screening for preterm pre-eclampsia. Ultrasound Obstet Gynecol 47:554–559CrossRefPubMed
16.
Zurück zum Zitat Agrawal S, Shinar S, Cerdeira AS, Redman C, Vatish M (2019) Predictive performance of PlGF (Placental Growth Factor) for screening preeclampsia in asymptomatic women: a systematic review and meta-analysis. Hypertension 74(5):1124–1135CrossRefPubMed Agrawal S, Shinar S, Cerdeira AS, Redman C, Vatish M (2019) Predictive performance of PlGF (Placental Growth Factor) for screening preeclampsia in asymptomatic women: a systematic review and meta-analysis. Hypertension 74(5):1124–1135CrossRefPubMed
17.
Zurück zum Zitat Rana S, Powe CE, Salahuddin S, Verlohren S, Perschel FH, Levine RJ, Lim KH, Wenger JB, Thadhani R, Karumanchi SA (2012) Angiogenic factors and the risk of adverse outcomes in women with suspected preeclampsia. Circulation 125(911–919):13 Rana S, Powe CE, Salahuddin S, Verlohren S, Perschel FH, Levine RJ, Lim KH, Wenger JB, Thadhani R, Karumanchi SA (2012) Angiogenic factors and the risk of adverse outcomes in women with suspected preeclampsia. Circulation 125(911–919):13
18.
Zurück zum Zitat Cetin I, Mazzocco MI, Giardini V, Cardellicchio M, Calabrese S, Algeri P, Martinelli A, Todyrenchuk L, Vergani P (2017) PLGF in a clinical setting of pregnancies at risk of Preeclampsia and/or Intrauterine Growth Restriction. J Matern Fetal Neonatal Med 30(2):144–149CrossRefPubMed Cetin I, Mazzocco MI, Giardini V, Cardellicchio M, Calabrese S, Algeri P, Martinelli A, Todyrenchuk L, Vergani P (2017) PLGF in a clinical setting of pregnancies at risk of Preeclampsia and/or Intrauterine Growth Restriction. J Matern Fetal Neonatal Med 30(2):144–149CrossRefPubMed
20.
Zurück zum Zitat Lobmaier SM, Figueras F, Mercade I, Perello M, Peguero A, Crovetto F, Ortiz JU, Crispi F, Gratacos E (2014) Angiogenic factors vs Doppler surveillance in the prediction of adverse outcome among late-pregnancy small-forgestational-age fetuses. Ultrasound Obstet Gynecol 43:533–540CrossRefPubMed Lobmaier SM, Figueras F, Mercade I, Perello M, Peguero A, Crovetto F, Ortiz JU, Crispi F, Gratacos E (2014) Angiogenic factors vs Doppler surveillance in the prediction of adverse outcome among late-pregnancy small-forgestational-age fetuses. Ultrasound Obstet Gynecol 43:533–540CrossRefPubMed
Metadaten
Titel
The role of the PLGF in the management of pregnancies complicated with fetal microsomia
verfasst von
Athena P. Souka
M. I. Chatziioannou
A. Pegkou
P. Antsaklis
G. Daskalakis
Publikationsdatum
28.03.2023
Verlag
Springer Berlin Heidelberg
Erschienen in
Archives of Gynecology and Obstetrics / Ausgabe 4/2024
Print ISSN: 0932-0067
Elektronische ISSN: 1432-0711
DOI
https://doi.org/10.1007/s00404-023-07012-w

Weitere Artikel der Ausgabe 4/2024

Archives of Gynecology and Obstetrics 4/2024 Zur Ausgabe

Alter der Mutter beeinflusst Risiko für kongenitale Anomalie

28.05.2024 Kinder- und Jugendgynäkologie Nachrichten

Welchen Einfluss das Alter ihrer Mutter auf das Risiko hat, dass Kinder mit nicht chromosomal bedingter Malformation zur Welt kommen, hat eine ungarische Studie untersucht. Sie zeigt: Nicht nur fortgeschrittenes Alter ist riskant.

Fehlerkultur in der Medizin – Offenheit zählt!

Darüber reden und aus Fehlern lernen, sollte das Motto in der Medizin lauten. Und zwar nicht nur im Sinne der Patientensicherheit. Eine negative Fehlerkultur kann auch die Behandelnden ernsthaft krank machen, warnt Prof. Dr. Reinhard Strametz. Ein Plädoyer und ein Leitfaden für den offenen Umgang mit kritischen Ereignissen in Medizin und Pflege.

Mammakarzinom: Brustdichte beeinflusst rezidivfreies Überleben

26.05.2024 Mammakarzinom Nachrichten

Frauen, die zum Zeitpunkt der Brustkrebsdiagnose eine hohe mammografische Brustdichte aufweisen, haben ein erhöhtes Risiko für ein baldiges Rezidiv, legen neue Daten nahe.

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.